From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Last Updated: Thursday, February 20, 2025

The distress thermometer (DT) survey was completed by 68% of 1,011 new multiple myeloma (MM) patients. Noncompletion was associated with being non-Hispanic Black, residing in a socially vulnerable neighborhood, having a Karnofsky Performance Status < 90, and recent consults. Nonrespondents were less likely to receive a stem cell transplant. The median distress score among respondents was 3%, with 22% reporting 0 distress. Distress correlated with being female and disease stage.

European Journal of Haematology
Advertisement
News & Literature Highlights

US Food & Drug Administration

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

Clinica Chimica Acta; International Journal of Clinical Chemistry

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

New England Journal of Medicine

Teclistamab in multiple myeloma with one to three previous lines of therapy

Annals of Medicine and Surgery

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

The Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

American Journal of Blood Research

Therapy-related B-cell acute lymphoblastic leukemia after treatment for multiple myeloma

Cancer Epidemiology

Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná

Molecular and Cellular Probes

The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma

The FEBS Journal

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Transplantation and Cellular Therapy

Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Advertisement
Advertisement